首页   按字顺浏览 期刊浏览 卷期浏览 Polymorphisms ofNAT2in relation to sulphasalazine-induced agranulocytosis
Polymorphisms ofNAT2in relation to sulphasalazine-induced agranulocytosis

 

作者: Mia Wadelius,   Elisabet Stjernberg,   Bengt-Erik Wiholm,   Anders Rane,  

 

期刊: Pharmacogenetics  (OVID Available online 2000)
卷期: Volume 10, issue 1  

页码: 35-41

 

ISSN:0960-314X

 

年代: 2000

 

出版商: OVID

 

关键词: NAT2;polymorphism;sulphasalazine;agranulocytosis

 

数据来源: OVID

 

摘要:

Agranulocytosis is a rare, but serious adverse reaction to sulphasalazine. The polymorphic enzymeN-acetyltransferase 2 (NAT2) plays an important role in the metabolism of sulphasalazine. This study was conducted to analyse whether the risk of sulphasalazine-induced agranulocytosis is increased in slow acetylators. Patients were treated for inflammatory disease, mostly joint disease, with a mean dose of 2 g sulphasalazine daily. Thirty-nine patients reacted with agranulocytosis, while 75 patients had been treated for a minimum of 3 months without haematological side-effects. A population-based control panel of 448 individuals was used for comparison. All subjects were genotyped forNAT2by polymerase chain reaction followed by restriction enzyme digestion. The six most common allelic variants were analysed:NAT2*4,NAT2*5A,NAT2*5B,NAT2*5C,NAT2*6andNAT2*7. The proportion of slow acetylators was significantly higher in patients with sulphasalazine-induced agranulocytosis (69%) and population-based controls (64%) compared to patients who tolerated sulphasalazine (45%); odds ratio 2.71 [95% confidence interval (CI) 1.20; 6.15],P = 0.015, and odds ratio 2.17 (95% CI 1.32; 3.56),P = 0.002, respectively. Patients who developed agranulocytosis did not differ from population-based control subjects in the frequency of slow acetylators; odds ratio 1.25 (95% CI 0.62; 2.53),P = 0.535. The risk of agranulocytosis did not appear to be increased in slow acetylators, provided that the difference compared with sulphasalazine-treated control subjects was not due to a predominance of fast acetylators among patients with inflammatory joint disease. Instead, selection bias was suspected since more slow acetylators may have discontinued sulphasalazine therapy because of drug-intolerance.

 

点击下载:  PDF (329KB)



返 回